『The Dr Suzette Glasner Podcast』のカバーアート

The Dr Suzette Glasner Podcast

The Dr Suzette Glasner Podcast

著者： Dr. Suzette Glasner
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 Dr. Glasner is a clinical psychologist, addiction scientist, award-winning author, and Associate Professor of Psychiatry at UCLA in the David Geffen School of Medicine. The Dr. Suzette Glasner podcast discusses the latest advances in addiction science, trends in alcohol and other substance use, misuse, and addiction across the lifespan, and how to use the science underlying addictive behaviors and the effects of substance use on the brain to shape our health behaviors and every day lives.

drglasner.substack.comDr. Suzette Glasner 心理学 心理学・心の健康 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Ep. 51: Joe Rogan on Ibogaine: What the Science Actually Says | The Dr. Suzette Glasner Podcast

    Ep. 51: Joe Rogan on Ibogaine: What the Science Actually Says | The Dr. Suzette Glasner Podcast
    2026/04/26
    When Joe Rogan recently called Ibogaine a near-miraculous cure for opioid addiction — and the White House announced it would accelerate federal research into psychedelic medicines including Ibogaine — a powerful narrative took hold: one dose, addiction gone. The viral statistic? An 80% cure rate.But what does the research actually say?In this episode, addiction scientist and clinical psychologist Dr. Suzette Glasner traces that 80% number back to its potential sources in the published research literature — and walks through what the studies to date have actually shown. Dr. Glasner explains the data through the lens of conservative methodology for interpreting treatment success rates, which suggests that the outcomes are closer to 50% abstinent at one month and 30% at one year. That’s still a meaningful signal worth investing in. It’s just not a miracle cure.Watch the full episode here:Dr. Glasner also unpacks what Ibogaine is and why it’s drawn the attention of addiction researchers — particularly its action in the brain’s reward circuit. She gets into the cardiac risks and how they can be reduced before and during treatment (e.g., cardiac screening, EKG monitoring during the session, and co-administered magnesium). 🧠 Key TakeawaysThe bottom line: the scientific signal is real, and accelerated federal investment in rigorous trials is genuinely needed. But the gap between what the evidence shows and what people are hearing in viral podcast clips is where people can get hurt. And while we wait for clinical trials to be completed, FDA-approved medications for opioid use disorder already exist, save lives, and are available right now.🔍 Episode Breakdown00:00 Joe Rogan and the ibogaine "miracle" story00:47 The "80% cured, 90%+ on the second dose" claim01:22 Trump's executive order accelerating psychedelic research01:59 Why this addiction scientist is excited — and concerned04:14 Three questions this episode answers04:35 What ibogaine is06:18 How ibogaine works in the brain: GDNF and the reward circuit08:18 What the clinical evidence actually shows10:26 Breaking down the 80% figure13:50 The 2024 Stanford TBI study and the gap in the evidence15:40 The safety conversation that isn't happening: hERG and QT17:56 Documented deaths and why cardiac monitoring matters19:11 Dr. Glasner’s final take and practical guidanceListen to Episode 51 for an evidence-based look at what Ibogaine can — and can’t — do, and why the gap between the science and the headlines matters.📩 Questions or topic suggestions? Email AskDrGlasner@gmail.com 🔗 Subscribe for evidence-based discussions on addiction, recovery, and mental health : www.YouTube.com/@drglasner This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit drglasner.substack.com
    続きを読む 一部表示
    22 分
  • Ep. 50: Can GLP-1s Reduce Cravings? Rethinking Addiction and the Brain

    Ep. 50: Can GLP-1s Reduce Cravings? Rethinking Addiction and the Brain
    2026/04/20

    In this episode, Dr. Suzette Glasner explores a rapidly emerging question: could medications like Ozempic and Wegovy do more than support weight loss—and actually reduce cravings for alcohol and other substances?

    The conversation is sparked by Oprah Winfrey’s recent reflection that after starting a GLP-1 medication, she lost her desire to drink alcohol—without trying.

    Drawing on the latest research, Dr. Glasner breaks down how GLP-1 medications work in the brain, particularly their effects on dopamine and the brain’s reward system, and why this may lead to reduced cravings not just for food, but for alcohol, nicotine, and other substances.

    You can watch the full episode on The Dr. Suzette Glasner Podcast here:

    She also reviews findings from large-scale studies involving tens of thousands of individuals, showing significantly lower rates of alcohol use disorder and relapse among people taking medications like semaglutide, along with emerging evidence across other substances.

    Beyond the science, this episode explores a deeper shift in how we understand addiction—from a model centered on willpower and choice to one rooted in brain biology. As widely used medications begin to impact craving itself, they may not only change treatment approaches, but also reduce the stigma that prevents many people from seeking help.

    Finally, Dr. Glasner discusses who might benefit from these medications, important limitations of the current research, and why GLP-1s should be viewed as a potential tool—not a cure—within a broader, evidence-based approach to addiction care.

    If you or someone you care about is struggling with alcohol or substance use, this episode offers a clear, grounded, and clinically informed perspective on where this field is headed.

    ⸻

    Have a question about today’s episode? Or a topic you’d like me to cover in a future episode?

    Email: askdrglasner@gmail.com

    ⸻

    #GLP1 #Ozempic #Wegovy #Addiction #AddictionRecovery #AlcoholUseDisorder #MentalHealth #BrainHealth #Dopamine #Cravings #SubstanceUse #ObesityMedicine #HealthPodcast #Psychiatry #Wellness



    This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit drglasner.substack.com
    続きを読む 一部表示
    11 分
  • Ep. 49: Is It Really ADHD? How Smartphone Use and Digital Addiction are Disrupting Attention

    Ep. 49: Is It Really ADHD? How Smartphone Use and Digital Addiction are Disrupting Attention
    2026/04/12

    We’re seeing more attention problems than ever—especially in kids.But what if it’s not always ADHD?And what if our smartphones are playing a bigger role than we think?

    In this episode, Dr. Suzette Glasner explores the growing conversation around ADHD—highlighted in part by Mel Robbins’ reflections on the nuances of diagnosis, especially in girls — and examines an often overlooked question:

    What if some of the attention difficulties we’re seeing today are not just ADHD, but are being shaped by constant smartphone use—scrolling, notifications, and the pull to check our devices throughout the day?

    From kids who can’t sit through homework without reaching for a device, to adults who find themselves checking their phones every few minutes, these patterns are becoming so common that they can be mistaken for something else entirely.

    As rates of inattention, distractibility, and difficulty focusing continue to rise in both children and adults, this episode takes a closer look at how excessive digital media use—particularly social media, gaming, and constant device engagement—may be influencing the brain in ways that can closely resemble ADHD.

    You can watch the full episode on The Dr. Suzette Glasner Podcast here:

    Dr. Glasner breaks down the latest research on how technology affects attention, impulse control, and reward pathways, including findings that suggest high-frequency digital media use may contribute to the development of attention problems over time. She also explores how patterns of addictive behavior around technology can reinforce these symptoms, making it increasingly difficult to disengage and sustain focus.

    Through clinical examples, this episode highlights the important distinction between ADHD as a neurodevelopmental condition and attention challenges that may be learned—and potentially reversible—through environmental and behavioral factors.

    If you or someone you care about is struggling with focus, attention, or constant device use, this episode offers a thoughtful, evidence-based framework to better understand what may be driving those symptoms—and what you can do about it.

    ⸻

    Have a question about today’s episode? Or a topic you’d like me to cover in a future episode?

    Email: askdrglasner@gmail.com



    This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit drglasner.substack.com
    続きを読む 一部表示
    21 分
まだレビューはありません